Ceribell, INC 8-K filings

CeriBell, Inc. announced second quarter 2026 financial results, showcasing a 33% year-over-year revenue increase to $28.1 million, driven by strong account growth and product adoption.

CeriBell, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of two Class II directors and the ratification of its independent auditor.

CeriBell, Inc. announced first quarter 2026 financial results, showcasing a 29% year-over-year revenue increase to $26.5 million and raising full-year revenue guidance.

CeriBell, Inc. announced robust financial results for Q4 and full year 2025, driven by significant revenue growth and critical FDA regulatory milestones.

Ceribell, Inc. announced its LVO stroke detection and monitoring solution received FDA Breakthrough Device Designation, positioning it as the first point-of-care EEG technology for this indication.

CeriBell, Inc. announced the resignation of Lucian Iancovici from its Board of Directors, effective December 31, 2025, citing a focus on other professional ventures.

CeriBell, Inc. announced the extension of two significant office leases in Sunnyvale, California, securing its operational footprint through January 2028.

Ceribell, Inc. announced FDA 510(k) clearance for its proprietary delirium screening and monitoring solution, marking the first such device.

Ceribell, Inc. announced FDA 510(k) clearance for its Clarity algorithm, making it the first and only AI-powered point-of-care EEG technology for detecting electrographic seizures in all ages, from pre-term neonates through adults.

CeriBell, Inc. announced robust third-quarter 2025 financial results, with total revenue increasing 31% year-over-year and an upward revision to its full-year revenue guidance.

CeriBell, Inc. has amended its supply agreement to include a Vietnamese manufacturing facility, diversifying its headband production and extending its contract with Everwin until 2027.

CeriBell, Inc. announced the appointment of Erica Rogers, a seasoned medtech executive, to its Board of Directors and Compensation Committee, effective September 17, 2025.

Ceribell, Inc. reported strong second quarter 2025 financial results, with total revenue increasing 38% year-over-year and raised its full-year 2025 revenue guidance.

Ceribell, Inc. has filed complaints against Natus Medical Incorporated with the U.S. International Trade Commission and the U.S. District Court for the District of Delaware, alleging infringement of six patents related to its EEG headband and electrode design and unfair competition.

CeriBell, Inc. has extended its critical exclusive license agreement with Stanford University, ensuring long-term rights to key patent-protected portable brain wave activity devices.

CeriBell, Inc. announced the successful re-election of its Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor during its 2025 Annual Meeting of Stockholders held on June 10, 2025.

Ceribell, Inc. announced a 42% increase in first-quarter revenue and raised its full-year 2025 revenue guidance.

CeriBell, Inc. provides estimates on the potential impact of U.S. tariffs on goods sourced from China, anticipating an 8-10 percentage point reduction in gross margins starting in Q4 2025.

CeriBell, Inc. has approved salary increases and incentive adjustments for its CEO, CFO, and CTO, effective April 1, 2025.

Ceribell announces a 45% increase in full-year 2024 revenue, driven by strong commercial traction and adoption of its Ceribell System.

Ceribell, Inc. presented at the 2025 J.P. Morgan Annual Healthcare Conference, showcasing its AI-powered EEG platform and highlighting significant growth and market potential.

CeriBell, a medical technology company, announced a 48% increase in revenue for the third quarter of 2024, driven by strong commercial adoption and expansion.

CeriBell, Inc. successfully closed its initial public offering, raising approximately $207.3 million, and implemented changes to its certificate of incorporation and bylaws.